ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.18
+0.00%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.22
From 52W high−33.44%
Volume85231.00
Market cap$157.74M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$4.22
From 52W high
−33.44%
Volume
85231.00
Market cap
$157.74M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
45.4
MomentumView details →
1D Return
+0.00%
YTD Return
+259.21%
SummaryUpdated Jun 1, 2026
AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Menlo Park, California. The company went public in March 2022 and focuses on developing innovative treatments for rare, chronic, and serious infectious diseases. AN2 Therapeutics is currently advancing its lead drug candidate through clinical trials, representing a specialized approach to addressing unmet medical needs in the infectious disease space.
Similar companies
Latest newsMore news →
AN2 Therapeutics granted inducement equity awards to two newly hired employees, including options to purchase 10,565 shares of its common stock.12d agoAN2 Therapeutics, Inc. announced that it will present a poster detailing the design of a planned Phase 2 trial of epetraborole in patients with polycythemia vera at the 18th AN2 Therapeutics, Inc..14d ago